29 related articles for article (PubMed ID: 31704732)
1. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Karakashev S; Zhu H; Wu S; Yokoyama Y; Bitler BG; Park PH; Lee JH; Kossenkov AV; Gaonkar KS; Yan H; Drapkin R; Conejo-Garcia JR; Speicher DW; Ordog T; Zhang R
Nat Commun; 2018 Feb; 9(1):631. PubMed ID: 29434212
[TBL] [Abstract][Full Text] [Related]
2. Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.
Martínez-Canales S; López de Rodas M; Nuncia-Cantarero M; Páez R; Amir E; Győrffy B; Pandiella A; Galán-Moya EM; Ocaña A
Cancer Med; 2018 May; 7(5):1896-1907. PubMed ID: 29575713
[TBL] [Abstract][Full Text] [Related]
3. ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells.
Chen CW; Buj R; Dahl ES; Leon KE; Aird KM
Heliyon; 2020 Sep; 6(9):e05097. PubMed ID: 33024871
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic Identification of a Breast-Specific Transcript Profile.
Chen C; Yang L; Rivandi M; Franken A; Fehm T; Neubauer H
Proteomics Clin Appl; 2020 Nov; 14(6):e2000007. PubMed ID: 32558282
[TBL] [Abstract][Full Text] [Related]
5. Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.
Moyano-Galceran L; Pietilä EA; Turunen SP; Corvigno S; Hjerpe E; Bulanova D; Joneborg U; Alkasalias T; Miki Y; Yashiro M; Chernenko A; Jukonen J; Singh M; Dahlstrand H; Carlson JW; Lehti K
EMBO Mol Med; 2020 Apr; 12(4):e11177. PubMed ID: 32115889
[TBL] [Abstract][Full Text] [Related]
6. Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells.
Melnikova M; Wauer US; Mendus D; Hilger RA; Oliver TG; Mercer K; Gohlke BO; Erdmann K; Niederacher D; Neubauer H; Buderath P; Wimberger P; Kuhlmann JD; Thomale J
Mol Oncol; 2020 Apr; 14(4):686-703. PubMed ID: 32037720
[TBL] [Abstract][Full Text] [Related]
7. EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies.
Samaržija I; Tomljanović M; Novak Kujundžić R; Trošelj KG
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230683
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
Ratz L; Brambillasca C; Bartke L; Huetzen MA; Goergens J; Leidecker O; Jachimowicz RD; van de Ven M; Proost N; Siteur B; de Korte-Grimmerink R; Bouwman P; Pulver EM; de Bruijn R; Isensee J; Hucho T; Pandey G; van Lohuizen M; Mallmann P; Reinhardt HC; Jonkers J; Puppe J
Breast Cancer Res; 2022 Jun; 24(1):41. PubMed ID: 35715861
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 Binding Protein 1 Responds to DNA Damage through the ATM-CHK2 Pathway.
Niwa Y; Kamimura K; Ogawa K; Oda C; Tanaka Y; Horigome R; Ohtsuka M; Miura H; Fujisawa K; Yamamoto N; Takami T; Okuda S; Ko M; Owaki T; Kimura A; Shibata O; Morita S; Sakai N; Abe H; Yokoo T; Sakamaki A; Kamimura H; Terai S
J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160302
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
[TBL] [Abstract][Full Text] [Related]
11. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer.
Leitner K; Tsibulak I; Wieser V; Knoll K; Reimer D; Marth C; Fiegl H; Zeimet AG
Sci Rep; 2020 Nov; 10(1):20412. PubMed ID: 33230143
[TBL] [Abstract][Full Text] [Related]
13. EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM.
Naskou J; Beiter Y; van Rensburg R; Honisch E; Rudelius M; Schlensog M; Gottstein J; Walter L; Braicu EI; Sehouli J; Darb-Esfahani S; Staebler A; Hartkopf AD; Brucker S; Wallwiener D; Beyer I; Niederacher D; Fehm T; Templin MF; Neubauer H
Mol Cancer Res; 2020 Feb; 18(2):278-286. PubMed ID: 31704732
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
15. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
16. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Zhan SJ; Liu B; Linghu H
Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
[TBL] [Abstract][Full Text] [Related]
17. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
18. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Jones BA; Varambally S; Arend RC
Mol Cancer Ther; 2018 Mar; 17(3):591-602. PubMed ID: 29726819
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]